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Studies of emerging diseases have focused
chiefly on the spectrum of different emerging
pathogens, epidemiologic reasons for emer-
gence, and interventions to control emergence.
The feasibility of disease control is hampered
by the potentially vast number of emerging and
reemerging pathogens, the diversity of geo-
graphic sources, the potential for rapid global
dissemination from these sources, and numer-
ous ecologic and social factors influencing
emergence (1-4). Disease control could be made
more manageable if the most dangerous
pathogens could be singled out for the most
intense study, surveillance, and control efforts.
Experts who have addressed this problem from
an epidemiologic but not an evolutionary
perspective disagree about the feasibility of
predicting and preventing the emergence of the
most damaging new pathogens (5-8). In this
perspective, I argue that improved understand-
ing of the evolution of virulence (defined
broadly as the harmfulness of an infection) can
make this goal more feasible in two ways: 1) by
facilitating identification and blocking of
pathogens that represent the greatest threat
should they become established in human
populations (e.g.,  Yersinia pestis during the
Middle Ages and human immunodeficiency
virus [HIV] during recent decades) and 2) by
providing methods for inhibiting the emergence
of particularly virulent variants of pathogens
that are already established in human
populations (e.g., the pathogen that caused the
1918 influenza pandemic and virulent,
antibiotic-resistant strains of  Staphylococcus
aureus).
Modern understanding of the evolution of
virulence focuses on a tradeoff to which
pathogens are subjected: the competitive
benefits that pathogens accrue through in-
creased exploitation of hosts and the costs that
result from any effects of disease that reduce
infectious contact between infected and suscep-
tible hosts. The traditional view presumed that
natural selection would favor evolution toward
benign coexistence between host and parasite
(9-12). The modern view, however, stresses
that such benign coexistence will be unstable if
pathogens that exploit hosts to a greater degree
have more overall success across transmission
cycles than those that achieve benign coexist-
ence (13-17).
The primary assumption of this evolution-
ary argument is that increased virulence is
correlated with increased pathogen propaga-
tion (manifested as increases in pathogen
reproduction within hosts and/or pathogen
shedding from infected hosts). This correlation
need not be strong across host/pathogen
associations for the arguments to be valid;
differences in pathogenic mechanisms, for
example, could make the correlation virtually
undetectable when extremely different kinds of
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pathogens are compared. Rather, the tradeoff
argument states that for a given pathogen
(with its particular tropisms and pathogenic
mechanisms), mutations that increase the level
of host exploitation tend to increase harmful-
ness. The association between virulence,
exploitation, and pathogen propagation is
expected among “wild type” mutants, but not
among novel laboratory-generated virulent
ones. Because there are many routes to
increased virulence and laboratory-generated
variants are often not selected on the basis of
competitive superiority in vivo, the increased
virulence of variants generated in the
laboratory may not be linked to propagative
superiority. In contrast, natural selection
should eliminate any variants for which
increases in virulence are not linked to
increases in pathogen fitness.
The connection between virulence, host
exploitation, and pathogen propagation may be
indirect or direct. If the pathogenic mechanism
involves toxin production, a positive associa-
tion is expected between toxin production and
pathogen propagation.  In Vibrio cholerae, for
example, high toxin production is associated
with increased densities of vibrios in the fecal
material, apparently as a result of the toxin’s
flushing of competing organisms from the
intestinal tract (17).  In other organisms, the
association between virulence, host exploita-
tion, and pathogen propagation is more direct.
The human plasmodia that reproduce more
extensively often cause more severe illness and
are more life-threatening (16). Similarly, more
virulent strains of vector-borne dengue virus
reproduce more extensively in cell culture (18).
Growth rates of Salmonella typhimurium were
reduced by eliminating one of its virulence
plasmids and inhibiting the plasmid’s expres-
sion; introduction of an 8-kb region encoding
the spv genes restored increased growth rate
(19). Comparison of Shigella species suggests a
similar association between virulence and
pathogen reproduction (20).
Sexually transmitted pathogens show
analogous associations.  For the best studied
pathogen, HIV, more rapidly replicative HIVs
are associated with greater cellular destruc-
tion in vitro, more rapid destruction of the
immune system, and more rapid onset of AIDS
(21-35). Similarly, the more oncogenic sero-
types of human papilloma-viruses (HPV)
generate greater numbers of progeny by
interfering with the cell’s mechanisms for
restricting cell division (36). For both viruses,
increased viral loads are associated with
increased probability of transmission to
contacted persons (37-39), and HIV-1, which
propagates to higher densities than HIV-2, is
more transmissible per contact (40).
The association between virulence and
viral propagation in pathogens circulating
naturally in human populations therefore
supports the modern emphasis on a tradeoff
between the fitness benefits and the costs
accrued by pathogens as a function of changes
in host exploitation.
Transmission Associated with High
Virulence
Transmission from Immobile Hosts
Like the traditional view of host/parasite
coevolution, the modern view identifies host
illness as a potential liability for the pathogen.
When pathogens rely on the mobility of their
current host to reach susceptible hosts, the
illness caused by intense exploitation typically
reduces the potential for transmission. The
modern perspective on host/parasite coevolu-
tion differs from the traditional one, however,
in its emphasis on weighing these setbacks
against the benefits of exploitation: high
virulence can contribute to evolutionary
stability if the costs incurred by parasites from
exploitation-induced damage are particularly
small and/or the benefits obtained from
exploitation are particularly big. Thus, if host
immobilization has little negative effect on
transmission, pathogen variants that exploit
the host so intensely that it is immobilized will
reap the benefits of exploitation. Put more
generally, when the costs incurred from
transmission associated with immobilization
are small, the costs of exploitation should
outweigh the benefits at a higher level of
exploitation—and hence virulence—than would
occur if immobilization severely impaired
transmission (16).
Recognizing this version of the general
tradeoff led to several predictions: Because
vector-borne parasites can be transmitted
effectively from immobilized hosts, they should
evolve to a higher level of virulence thanVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 247
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directly transmitted parasites (16). Similarly,
aspects of human behavior and culture can
form “cultural vectors,” which  transmit
pathogens from immobile to susceptible hosts
(41). For example, diarrheal pathogens that are
largely waterborne should evolve to relatively
high levels of virulence because effective
transmission can occur even when infected
hosts are mobilized: persons carrying contami-
nated clothing and bedding, the water used for
washing bed sheets, and the movement of
contaminated water into drinking water
together act like a swarm of mosquitoes,
transmitting pathogens from the immobilized
host. Attendant-borne pathogens should also
become virulent. Attendant-borne transmis-
sion often occurs in hospitals, when nurses and
physicians transmit pathogens from one
immobilized patient to another. A reciprocal
process occurs when parasites rely on the
mobility of  susceptible persons rather than the
mobility of the infected hosts to reach the
susceptible persons. Parasites that are durable
in the external environment should thus evolve
toward a higher level of virulence than
nondurable pathogens because durable patho-
gens may remain viable in the environment
until the movement of susceptible individuals
brings them into contact with the pathogens.
Each of these hypotheses has been
evaluated and in each case the expected
association occurred: virulence is positively
associated with vector-borne transmission,
waterborne transmission, attendant-borne
transmission, and durability in the external
environment (Table 1). This evolutionary
framework, therefore, explains the diversity of
human parasites in a way that contrasts
starkly with the traditional view. Instead of
being seen as a sign of maladaption, the
severity of diseases such as malaria, tuberculo-
sis, smallpox, cholera, and typhoid fever is seen
as a consuequence of evolutionary adaptation
because the causative parasites do not rely on
host mobility for transmission. The tradeoffs
between the benefits and costs of exploitation,
therefore, favor evolution of relatively high
levels of exploitation for such pathogens and
hence high degrees of harm to the host.
Sexual Transmission
The evolutionary tradeoffs associated with
virulence in sexually transmitted diseases
involve the requirements for sexual transmis-
sion imposed on the pathogens by the sexual
behavior of the host. Short durations of
infections would be ineffective for most
sexually transmitted pathogens. If people
changed sex partners once per year, for
example, a pathogen that was rendered
noninfectious by immunologic defenses or the
host’s death within a few weeks would have
little chance of being transmitted. To survive,
the pathogen must be transmissible for a
period that extends into the time of the next
sexual partnership. To prosper, the pathogen
must be transmissible for periods that span
more than one change in sex partners;
therefore, sexually transmitted pathogens may
often need cell and tissue tropisms that keep
them from being eliminated by the immune
system for relatively long periods.
The evolutionary effects of changes in
sexual behavior on virulence may be strongly
influenced by tropisms that were present
before the behavior change. Increased poten-
tial for sexual transmission should favor
pathogen variants that reproduce more exten-
sively sooner after the onset of infection. If the
preexisting tropisms target nonessential cell
types, this selection for earlier reproduction
will have relatively little effect on virulence. If,
for example, people changed sex partners every
few days, the sexually transmitted pathogen
should evolve virulence levels much like those
of respiratory tract pathogens, which rely on
host mobility for transmission. Examples of
such pathogens are sexually transmitted
unicellular pathogens such as Neisseria
gonorrheae and Chlamydia trachomatis, which
tend to infect mucosal tissues and, therefore,
have relatively minor negative effects on the
survival of adult hosts. If, however, the
tropisms involve critical cells, the damage
associated with increased levels of host
exploitation should be more severe to the host.
HIV provides an example: HIV has a tropism
for helper T cells, which are critical regulators
of immunologic responses. Although a high
level of replication in these cells can be
tolerated over short periods, it eventually leads
(by mechanisms that are still being clarified) to
the decimation of this category of cells and the
collapse of the immune system.
If these arguments about evolutionary
forces and tissue tropisms are applicable toEmerging Infectious Diseases Vol. 2, No. 4—October-December 1996 248
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HIV, HIVs should be more virulent in areas
where the potential for sexual transmission is
greater. In accordance with this prediction,
HIV-2 tends to be less virulent than HIV-1;
moreover, evidence indicates that during the
early years of HIV infection in Africa, HIV-2
tended to be transmitted in populations having
a lower potential for sexual transmission
(17,20). The overall validity of this approach to
HIV virulence, however, will be better tested as
different variants of HIV emerge in different
geographic regions. Information about the
potential for sexual transmission can help
predict the evolution of HIV virulence in
different geographic areas. On the basis of the
evolutionary tradeoffs mentioned above, for
example, the type E HIV-1s that are circulating
in Thailand (where the potential for sexual
transmission has been great) are predicted to
be particularly virulent (17). Although this
prediction needs to be evaluated rigorously,
recently gathered data support the prediction:
the decline in CD4+ cell counts of persons
infected with HIV and the progression of illness
in these patients appear to be particularly
rapid in Thailand (43-44).
The most important application of this
evolutionary approach to HIV, however,
pertains to interventions that can be used to
control the future evolution of HIV. If the
inherent virulences of HIVs depend evolution-
transmission (48), type E HIV-1s have recently
been introduced from Southeast Asia. If a low
potential for sexual transmission favors
evolution toward mildness, the Japanese type
E viruses should become milder over the next
few decades.
Assessing the Threat Posed by Pathogens
Assessment Goals
Focusing investigative and intervention
efforts on the most significant disease threats
makes sense only if the threats can be reliably
assessed. The long-term threat depends on the
evolutionary stability of high pathogen viru-
lence, and the most dangerous pathogens are
those that threaten widespread persistence
with severely damaging manifestations. One of
the most important tasks in controlling
emerging diseases is to identify and block such
pathogens during the early stages of emer-
gence, or better yet, before they emerge. If the
most dangerous pathogens—the future analogs
of the causes of AIDS, malaria, smallpox,
tuberculosis, and cholera—could be effectively
blocked, the effort against emerging diseases
would be successful. If not, the effort may be
looked on as a failure in spite of successes
against pathogens that are less able to
effectively penetrate human populations or
relatively benign when they do establish
Table 1. Categories of pathogens that pose threats of being stably
harmful in human populations because of reduced dependence on
host mobility
Characteristics allowing Association with lethality Reference
transmission from
immobile hosts




water-borne lethality of diarrheal bacteria (42)
transmission correlated with tendencies for
waterborne transmission
attendant-borne lethality of E. coli correlated (20, 41)
transmission with duration of
attendant-borne cycling
durability in the lethality of respiratory-tract *
external environment pathogens correlated
with durability
*B. A. Walther and P. W. Ewald, unpublished manuscript
arily on the potential for sexual
transmission, interventions that
reduce this potential should have
a long-term evolutionary effect, as
well as widely recognized short-
term epidemiologic effects—in ad-
dition to reducing the spread of
HIV infection, such interventions
should reduce the harmfulness per
infection. Follow-up of persons
infected with HIV-1 for more than
a decade without deterioration of
the immune system indicates that
the mildness of the infections is
sometimes attributable to inher-
ently mild viruses (45-47). The
raw material for this evolutionary
change, therefore, appears to be
already present in the HIV gene
pool.
In Japan, which has a rela-
tively low potential for sexualVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 249
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themselves. The emergence, spread, and
persistence of pathogens with the characteris-
tics of rhinoviruses, for example, would not be
looked on as a great failure. The establishment
of such pathogens would hardly be noticed
against the current backdrop of mild to
moderately severe respiratory tract pathogens.
To identify pathogens that must be studied
and controlled most intensively, each pathogen
should be assessed for two characteristics that
are associated with high virulence: 1) an ability
to spread well from human to human (directly
or indirectly through vectors) rather than
infecting humans as dead-end hosts, and 2)
transmission features that select for high
levels of virulence.
The existing associations between virulence
and transmission characteristics (Table 1) can
be used to make such identifications. Table 2
offers a checklist that could be applied to each
emerging pathogen to determine whether it
makes the first cut in the process of identifying
the most dangerous candidates. Subsequent
analyses of the pathogens would then assess
the nature of any barriers that limit the
establishment of pathogens in human popula-
tions (e.g., the absence of suitable arthropod
vectors for large proportions of the year).
Durability
Although durability in various external
environments was quantified in detail by
microbiologists during the first half of this
century (49), modern studies have paid this
attribute little attention. Evolutionary consid-
erations, however, indicate that it should be
one of the first variables quantified when a new
pathogen is being studied. If a new, directly
transmitted pathogen can remain viable in the
external environment for many days to many
weeks, it falls in the category of especially
dangerous pathogens. If, for example, Ebola
virus were viable upon natural desiccation for
weeks instead of hours, its level of host
exploitation and potential for transmission
from exploited hosts would not be so
mismatched, and it, like smallpox virus, would
pose a much more serious threat. Durability in
the external environment depends largely on
environmental conditions (49), and thus
assessments of viability should cover all
feasible environmental conditions.
Vector-borne Transmission
The most serious threat involved in vector-
borne transmission comes from pathogens that
can be maintained by human/mosquito cycles
but are absent from suitable areas because of
historical accidents or past eradication cam-
paigns. Dengue and malaria are members of
this category; they have the potential to spiral
out of control immediately upon release into
areas with suitable vectors. Nonevolutionary
analyses of emerging infections recognize the
threat posed by these pathogens because their
damaging effects on human populations are
known.
Vector-borne pathogens that have not used
humans as the primary vertebrate host but
may be capable of doing so represent less easily
recognized threats. Evolutionary consider-
ations heighten concern because such vector-
borne pathogens are expected to become
increasingly harmful as they become adapted
to human/vector cycles of transmission (16).
Rift Valley fever virus provides an
example. For most of this century, this virus
was believed to infect humans only as dead-end
hosts. Although it was vector-borne in
ungulates, humans were seen as acquiring the
Table 2. First-level checklist for identifying the
most dangerous emerging pathogens. If the
answer to any of the questions is yes, the potential
for continuous transmission between humans
should be assessed. If this potential is high, the
pathogen should be considered particularly
dangerous.
Does it have a tendency for waterborne
transmission?
Is it vector-borne with the ability to use
humans as part of the life cycle?




If it is sexually transmitted, is it
mutation-prone with a tropism for
critical cell types or does it have
invasive or oncogenic tendencies?
*The hypothesized importance of needleborne transmission
has not yet been tested; it has been included in this listing on
the basis of the harmfulness of needleborne pathogens and
the hypothetical assocations between needleborne
transmission and virulence (17).Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 250
Perspectives
infection either when involved in
the slaughtering process or when bitten by
mosquitoes that had acquired infection from
other vertebrates. Recent outbreaks have
spread to an extent consistent with substantial
human/mosquito cycling, but the existence of
such cycling has not been conclusively
documented. If human/mosquito cycling is
occurring, the door is open for further
adaptation to humans and for evolution of
increased virulence in humans, increased
efficiency of human/vector transmission, and
increased spread through human populations.
Rift Valley fever virus viremias seem sufficient
for human/mosquito cycling, and the lethality
of the largest outbreaks was particularly high,
as one would expect if some evolution toward
increased virulence accompanied a temporary
establishment of human/mosquito cycles (50-
51). To assess the long-term threat posed by
Rift Valley fever virus and to block this virus
should it prove to be particularly threatening,
we need to emphasize the following research
priorities: 1) study the transmission of Rift
Valley fever virus in human/mosquito cycles, 2)
assess the potential for such transmission over
extended periods, and 3) evaluate the effects of
such transmission on virus virulence.
All emerging vector-borne pathogens need
not be viewed as equally threatening. For
example, Borrelia burgdorferi, the agent of
Lyme disease (an emerging vector-borne
pathogen in human populations in North
America), does not need to be monitored to
avoid its establishment as a human pathogen
because once emerged, it does not threaten to
spiral out of control; it is tick-borne, and
ongoing human/tick cycles are not feasible
because of the limited exposure of infected
humans to susceptible tick populations of the
appropriate instar. Tick- and mite-borne
rickettsiae do not present a great threat for
similar reasons.
Sexual Transmission
The tradeoff concerning sexually transmit-
ted pathogens may prove particularly useful in
identifying pathogens that are capable of
sexual transmission and have cell tropisms
that would cause severe damage if host
exploitation increased but have not had high
potential for sexual transmission. Human T-
cell lymphotropic virus (HTLV) is in this
category, even though by nonevolutionary
criteria it could be dismissed because it has
been geographically widespread in humans for
a long time (1). HTLV type 1 (HTLV-I) is less
damaging than HIV; it kills or severely
handicaps 5% to 10% of the people it infects,
generally decades after infection. Although
HTLV-I and HIV infections share many
characteristics, HTLV does not have HIV’s
high mutation rate and hence does not have the
potential for staying ahead of immune
responses and eventually decimating the
immune system. Instead, HTLV relies on
modes of transmission that do not expose it to
the immune system: proviral replication
through stimulation of host cell proliferation
and transmission through cell-to-cell contact.
A concern with HTLV is that a high potential
for sexual transmission may favor increased
rates of viral replication leading to increased
exposure to the immune system and increased
mutation rates (48).
A preliminary step toward evaluating the
threat posed by the emergence of particularly
virulent HTLVs is assessing whether HTLVs
exposed to different levels of potential for
sexual transmission vary in virulence. HTLV-I
infections tend to lead to leukemias and
lymphomas at younger ages in Jamaica, where
the potential for sexual transmission is high,
than in Japan, where potential for sexual
transmission is low (48). This difference also
occurs among North Americans of Japanese
and Caribbean descent (52), who presumably
are infected predominantly (if not exclusively)
by Japanese and Caribbean HTLVs, respec-
tively. The inherent virulence and mutation-
proneness of the Japanese and Caribbean
HTLVs need to be assessed. Similarly, HTLV
virulence needs to be better studied in regions
of Africa where it has been long endemic to
determine whether variations in HTLV viru-
lence are correlated with the potential for
sexual transmission.
Although mutation-prone sexually trans-
mitted viruses that infect critical cell types are
particularly threatening, sexually transmitted
viruses in general deserve special attention.
Even if a sexually transmitted virus invades
only epithelial cells and replicates with low
mutation rates, a high potential for sexualVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 251
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transmission may lead to evolution of in-
creased lethality. Death caused by HTLV-
induced lymphomas and leukemias is one
manifestation of the danger posed by an RNA
virus that replicates substantially in its DNA
form and hence is in a middle area within the
spectrum of mutation-proneness. HPVs illus-
trate dangers posed by sexually transmitted
viruses that, because they are DNA viruses, are
even further away from HIV on the mutation-
proneness continuum. The mechanism by
which HPV nudges infectious cells toward
cancer is associated with increased viral
replication; moreover, high potential for sexual
transmission (as indicated by the number of
lifetime sex partners) is a strong risk factor for
infection with the more oncogenic HPV
serotypes but not for the mild HPV serotypes
(53). This association supports the idea that
reductions in the potential for sexual transmis-
sion should cause evolution of reduced HPV
virulence. Specifically, as the potential for
sexual transmission decreases, the risk for
acquiring the oncogenic serotypes (vs benign
serotypes) should disproportionately decrease.
Similarly, if interventions prevent the poten-
tial for sexual transmission from increasing,
the emergence of oncogenic HPV serotypes
should be disproportionately suppressed.
Waterborne Transmission
Although such pathogens as Vibrio cholerae
O139 and Shigella dysenteriae type 1 threaten
emergence in countries with inadequate water
supplies, the threat is much lower in countries
with safe water supplies. Although such
pathogens continue to be brought into the
countries with safe water supplies by travelers
and commerce, the pathogens show little
potential for emergence. For example, a major
epidemic of S. dysenteriae type 1 spread from
Guatemala through Central America during
the early 1970s. It entered the United States in
several places but dissipated without any great
effort at containment. Its transmission was
studied in a Los Angeles neighborhood, where
each infection gave rise on average to about 0.4
new infections (54). Without amplification by
waterborne transmission, this outbreak, like
other introductions in the United States, was
self-limited (54). The situation at the other end
of Central America was similar. The S.
dysenteriae epidemic dissipated as it moved
into Costa Rica, where water supplies were
relatively pure (L. J. Mata, pers. comm.).
Attendant-borne Transmission
Emerging hospital-acquired pathogens may
pose one of the greatest and most controllable
threats to people in countries like the United
States, where more than 5% of hospital
admissions and about 14% of intensive care
patients acquire infections during their stay
(55-57).  According to some estimates,
nosocomial infections rank among the ten
leading causes of death in the United States
(56), with dangerous bloodstream infections
approximately doubling during the 1980s (58).
Although high virulence has been docu-
mented in pathogens involved in nosocomial
outbreaks (59-63), the damage caused by
nosocomial pathogens has generally been
attributed to the state of hospitalized patients,
who may be compromised by underlying
disease, immunosuppressive drugs, and inva-
sive procedures. These factors, however, do not
explain why nosocomial pathogens, such as
Staphylococcus aureus often cause symptom-
atic infections in hospital staff (60) but rarely
in persons in the outside community. They also
do not explain the association between the
extent of nosocomial transmission and the
virulence of infection, or the differences in
symptomatic infections among otherwise
healthy babies (17,20,41). In a New York City
hospital, for example, where attendant-borne
transmission rates were very low, only
approximately one of 30 babies with S. aureus
were symptomatic (64). Among nosocomial
outbreaks of endemic disease, the analogous
proportion may be 5- to 10-fold higher (65).
Without an evolutionary framework for
understanding pathogen virulence, research-
ers would have no reason for expecting to find
particularly virulent endemic pathogens in
hospitals. The only serious attempts to explain
the apparently high-level of pathogen virulence
in hospitals involved the linking of virulence to
another characteristic associated with hospi-
tals: antibiotic resistance. The emergence of
antibiotic-resistant organisms in hospitals in
concert with the use of the antibiotics (66) led
researchers to conclude that high levels of
antibiotic use caused the emergence of
resistant organisms and to speculate that
antibiotic-resistant organisms might be inher-Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 252
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ently more virulent than their antibiotic-
sensitive counterparts (67). Yet when infec-
tions caused by resistant nosocomial organ-
isms are compared with sensitive (generally
nosocomial) infections, the former are only
sometimes found to be associated with more
severe infections. Even when they are
associated with more severe disease (62,63),
any differences in inherent virulence tend to be
confounded with other factors, such as
increased severity due to lowered effectiveness
of antibiotics. The increased severity of
disease, however, is sometimes associated with
resistance to antibiotics other than the one
being used (61), suggesting that the increased
damage is not simply a result of ineffective
antibiotics. The presence of virulence-enhanc-
ing bacterial characteristics in damaging,
resistant nosocomial strains (63,68) also
suggests a link between nosocomial transmis-
sion, antibiotic resistance, and virulence:
antibiotic-resistant strains may have been
particularly virulent because they were
nosocomial, but this virulence was not
apparent in many of the comparisons because
the sensitive strains were also nosocomial.
Although the controversy regarding viru-
lence and antibiotic resistance in hospital-
acquired infections can be explained by the
hypothesized connection between attendant-
borne transmission and the evolution of both
virulence and antibiotic resistance, none of the
investigations of the topic made measurements
that would allow assessment of the connection
between attendant-borne transmission and the
emergence of variants with increased viru-
lence. The critical measure is the harmfulness
per person housing the organisms in question,
and the critical comparison is between
nosocomial and community-acquired strains.
Among persons that harbor nosocomial strains
of S. aureus, for example, the proportion that
show symptomatic infection could be compared
with the analogous proportion of matched
persons who are harboring community strains.
After virulence-enhancing mechanisms are
well understood, pathogens can be assayed for
their virulence directly. Thus Clostridium
difficile pathogens isolated from prolonged
nosocomial outbreaks are predicted to be more
toxigenic than C. difficile isolated from the
outside community. Similarly, nosocomial
Escherichia coli are predicted to have
virulence-enhancing characteristics (e.g., inva-
siveness, adherence) (69) more often than
community strains.
Further knowledge about virulence  en-
hancing mechanisms and development of
techniques for rapid detection (e.g., [72-75])
should offer opportunities for carefully con-
trolled experiments to test whether reduction
in attendant-borne transmission causes a
greater decline in the inherent virulence of
nosocomial pathogens in experimental hospi-
tals than in control hospitals in which
interventions are not imposed. Long-term
follow-up should clarify the degree to which
attendant-borne transmission may foster the
emergence of virulent variants among both
established human pathogens (e.g., S. aureus,
E. coli) and new or newly recognized pathogens
(e.g.,  Serratia spp., and Pseudomonas
aeruginosa).
Harmful, often antibiotic-resistant, hospi-
tal-acquired pathogens can readily emerge
beyond a hospital’s boundary, when patients
are moved, or attendants move between
hospitals; the documentation is particularly
strong for dangerous variants of E. coli and S.
aureus (62,74-78). The degree to which
emerging nosocomial pathogens spill over to
generate outbreaks in the outside community
is not well understood, but evidence suggests
that this spillover represents a substantial
threat when the organisms can infect healthy
people. When large-scale communitywide
epidemics of pathogenic E. coli have occurred,
for example, transmission in hospitals often
was strongly implicated. During 1953 and
1954, an E. coli epidemic advanced up the East
Coast of the United States from the Carolinas
through New England; “As it spread, explosive
outbreaks were limited to institutions, hospital
wards, and newborn nurseries” (59). A focal
study of the U.S. Army Hospital at Fort
Belvoir, Virginia, indicated that the epidemic
strain was brought into the hospital by infected
people in the community, with the proportion of
inpatient to outpatient cases reversing dra-
matically during the hospital’s 5-month
outbreak (59). Similarly, during the winter of
1961, in an outbreak in Chicago and adjacent
communities in Indiana, about 5% of the
infants were affected, and nearly half of the
affected infants had direct or indirect contact
with one of the 29 involved hospitals just beforeVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 253
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their illnesses (75).
Studies of S. aureus have also shown that
nosocomial and community outbreaks are
sometimes synchronous with transmission
occurring in both directions between the
hospital and the outside community (79-80).
The long-term consequences of emergence of
nosocomial strains for the outside community,
however, still need to be assessed.  The
possibility that nosocomial pathogens may
tend to be not only more resistant to
antibiotics, but also more inherently virulent
lends some urgency to this need.
Almost no work has been done to determine
the potential of pathogens thought to be almost
exclusively associated with nosocomial infec-
tion (e.g., Enterococcus, C. difficile) to take hold
in the outside community. The high durability
in the external environment of many nosoco-
mial pathogens heightens the need for
additional information. Durable pathogens
that can infect uncompromised hosts (e.g.,
antibiotic-resistant  S. aureus and to a lesser
extent  C. difficile) possess the basic character-
istics that damaging organisms need to spread
in the outside community.  Durable organisms
unable to infect healthy people pose a relatively
low threat, but this inability is often presumed.
Any transmission of durable nosocomial
organisms like P. aeruginosa from patients
after discharge heightens the threat to the
outside community by providing an avenue for
further adaptation to humans. Molecular
analyses that allow reconstruction of epidemio-
logic patterns (e.g., molecular phylogenetics)
could be used to improve assessments of the
degree to which nosocomial pathogens can
emerge in the outside community; such studies
need to provide quantitative assessments not
only of the threats posed by nosocomial
pathogens in their current state, but also of
their potential to breach by evolution the
barriers that have inhibited their broader
spread in the past.
Conceptual Innovation, Explanatory
Power, and Precision
Dangerous Emergences of the Past
Each of the organisms that caused deva-
stating epidemics over the past 5 centuries,
would have been identified as an extremely
dangerous pathogen by the criteria proposed
here. Y. pestis, for example, is durable in the
external environment (49) and is vector-borne.
Its threat is lower now than centuries ago when
fleas and rats were abundant domiciliary
inhabitants, but it still represents a threat
where these hosts are present.
The periodic emergence of yellow fever in
European and American cities during the 18th
and 19th centuries took a heavy toll; the 1878
epidemic, for example, killed about a quarter of
the population of Memphis, Tennessee (81). If
yellow fever virus were first encountered
today, it would be recognized as an important
threat because it is vector-borne and can be
transmitted indefinitely through human/mos-
quito cycles.
With regard to the emergence of virulent
variants from established pathogens, the
influenza viruses circulating at the Western
Front during World War I would be considered
dangerous because barriers to transmission
from immobile hosts were removed by cultural
practices and because influenza virus is
mutation prone (17,20). It is, therefore, not
surprising that the Western Front has been
identified as the source of the highly lethal
variants of the 1918 influenza pandemic and
that a pandemic of this severity has never
recurred (17). More importantly, evolutionary
considerations suggest that such a lethal
pandemic will not recur  unless influenza
viruses are again exposed to opportunities that
allow transmission from immobile hosts, as
they are on poultry farms where highly lethal
influenza outbreaks periodically emerge (17).
Uncertainty about the Dangerous
Epidemics of the Future
These arguments about the evolution of
virulence provide only coarse approximations
of the selective processes in pathogen
populations. To determine whether the
implications of these arguments need to be
substantially modified, we need empirical
studies that evaluate these arguments against
alternative explanations. Considering the
current state of uncertainty, some might argue
that it is dangerous to incorporate the current
coarse understanding of the evolution of
virulence into policy making. But failing to
incorporate this understanding is dangerous.Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 254
Perspectives
If we do not adjust investments to take into
account the evolutionary arguments, and the
arguments prove correct, the reduction in
death and illness per unit investment will be
lower than it could have been. If we do adjust
investments on the basis of these evolutionary
arguments, and the arguments prove wrong,
the nonevolutionary benefits of the invest-
ments would still be obtained.
Although the precise mechanisms that
increase virulence in pathogens in the high-
risk categories still need to be clarified, the
associations (Table 1) are strong. One could
argue, for example, that durable or waterborne
pathogens are more harmful because hosts
tend to pick up a greater diversity of genotypes
from the environment when pathogens are
more durable or are mixed in water; if the
within-host genetic variability of such patho-
gens is greater, they would have more potential
for within-host competition, which could favor
the evolution of increased virulence. By this
argument, factors such as durability, vector-
borne transmission, and waterborne transmis-
sion would increase virulence indirectly by
increasing within-host genetic variation. With
regard to the prevention of the emergence of
highly virulent disease, uncertainties about
mechanisms are not critical. Whether the
effects of these factors are direct or indirect,
elimination of the factors should discourage the
emergence of severe disease and favor the
decrease of highly virulent pathogens.
Decisions to invest in interventions
without certainty about mechanisms is not new
to the health sciences. The hygienic interven-
tions to control hospital acquired diseases and
the purification of water supplies to control
cholera were appropriately advocated on the
basis of epidemiologic data (from Ignaz
Semmelweis and John Snow) a half century
before the causative agents of these or any
other infectious diseases were first identified.
Jenner’s smallpox vaccine program was
accepted globally more than a century before
viruses were discovered or the mechanisms by
which vaccines provide protection
were understood. Even now the mechanisms by
which the immune system provides protection
encompass major areas of uncertainty. This
uncertainty is evidenced, for example, by the
controversies about the importance of the
different legs of the immune system (such as
cytotoxic T cells, neutralizing antibody, and
subsets of helper T cells) in HIV pathogenesis.
If the evolutionary arguments are correct,
the emergence of the most harmful diseases can
be countered not only for pathogens that are
recognized as threats but also for those posing
threats that are not yet recognized. Providing
pure water supplies, reducing attendant-borne
transmission, and reducing vector-borne
transmission preferentially from ill people
(e.g., by providing mosquito-proof houses [17])
should guard against the emergence of virulent
pathogens, whether the pathogens are uniden-
tified or are highly virulent variants of
identified human pathogens. An understand-
ing of the evolutionary determinants of
virulence may thus make surveillance and
prompt intervention much more manageable.
The emphasis thus is on suppression of the
emergence of particularly virulent variants
rather than suppression of the emergence of
new disease organisms. The expectation is that
the frequency of disease will drop even though
the frequency of individuals harboring
organisms may decline little if at all. The data
on decentralization of nursery/maternity wards,
for example, indicate that the rates of
nosocomial infection decline among mothers
and babies, even though the rates at which
babies harbor pathogens (colonization plus
infection) do not decline (82). Indeed the
disagreement about the value of rooming-in as
a mode of infection control (82) can be
attributed to a failure to distinguish the
prevalence of disease organisms from the
prevalence of disease. Controversies about the
value of waterborne transmission can be traced
to a similar failure (17).
The lead article of the first issue of this
journal was entitled, “Emerging infections:
getting ahead of the curve” (4). I propose that
integrating evolutionary principles with epide-
miology would enhance our ability to stay
ahead of the curve. Evolutionary insights
should increase our ability to distinguish
emerging pathogens according to the long-term
threat that they pose and thereby adjust
investments in accordance with the threat.
Knowledge of the evolution of virulence should
also guide us to identify for each pathogen the
critical data that will allow us to make this
assessment. Finally, evolutionary consider-
ations should allow identification ofVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 255
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infrastructural investments that will  guard
against the most dangerous pathogens, even if
they are not blocked by surveillance and
containment efforts and even if they have not
yet been identified or are never identified as
emerging pathogens.
Dr. Ewald is a professor in the Department of
Biology at Amherst College. Trained in ecology and
evolutionary biology, he works at the interface of
these areas with epidemiology, focusing on the
evolution of virulence among infectious diseases of
humans and insects.
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